<SEC-DOCUMENT>0001493152-24-046564.txt : 20241118
<SEC-HEADER>0001493152-24-046564.hdr.sgml : 20241118
<ACCEPTANCE-DATETIME>20241118170508
ACCESSION NUMBER:		0001493152-24-046564
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241118
DATE AS OF CHANGE:		20241118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Glucotrack, Inc.
		CENTRAL INDEX KEY:			0001506983
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				980668934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41141
		FILM NUMBER:		241472303

	BUSINESS ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070
		BUSINESS PHONE:		972 (8) 675-7878

	MAIL ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GlucoTrack, Inc.
		DATE OF NAME CHANGE:	20220328

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integrity Applications, Inc.
		DATE OF NAME CHANGE:	20101203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:GCTK="http://glucotrack.com/20241112">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_GCTK_glucotrack.com_20241112 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20241112_20241112 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001506983 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000004" name="dei:EntityCentralIndexKey">0001506983</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gctk-20241112.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20241112__20241112_zvPCMkudBHVg"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_909_edei--DocumentPeriodEndDate_c20241112__20241112_zqU1kmDeL8ph"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 12, 2024</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20241112__20241112_zUpMEfXXc9c1"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000011" name="dei:EntityRegistrantName">GLUCOTRACK,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20241112__20241112_zsunfA36T3Qg"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFileNumber_c20241112__20241112_z3KRMHi5mFS8"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000013" name="dei:EntityFileNumber">001-41141</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20241112__20241112_zogQK7SG9wD6"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-0668934</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20241112__20241112_zVsWUN2OFCsa"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000015" name="dei:EntityAddressAddressLine1">301
    Rte. 17 North</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20241112__20241112_zx4lWtZkMnHi"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000016" name="dei:EntityAddressAddressLine2">Ste. 800</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20241112__20241112_zFjA1DrYEim9"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000017" name="dei:EntityAddressCityOrTown">Rutherford</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20241112__20241112_z2p07e6hcTZ"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000018" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityAddressPostalZipCode_c20241112__20241112_zoC4dxVxF5R6"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000019" name="dei:EntityAddressPostalZipCode">07070</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive
    offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span id="xdx_902_edei--CityAreaCode_c20241112__20241112_z0oF2UDtttJ6"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000020" name="dei:CityAreaCode">(201)</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20241112__20241112_zMNUVhhQG3oe"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000021" name="dei:LocalPhoneNumber">842-7715</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--WrittenCommunications_c20241112__20241112_zXtiZ08kRcN7"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SolicitingMaterial_c20241112__20241112_z82isa90kDke"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20241112__20241112_zVe3PSmSbwm8"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20241112__20241112_zt8rVU3QJFDh"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--Security12bTitle_c20241112__20241112_ziWjok9FuS68"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000026" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--TradingSymbol_c20241112__20241112_zGoB1GKUvG04"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000027" name="dei:TradingSymbol">GCTK</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--SecurityExchangeName_c20241112__20241112_zm4GoG5qSgh7"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market
    LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.15pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167; 240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20241112__20241112_zYOobe2bh4Sd"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder
Support Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, on November 14, 2024, Glucotrack, Inc., a Delaware corporation (the &#8220;Company&#8221;) closed a best efforts
public offering (the &#8220;Offering&#8221;) for the offer and sale of an aggregate of (i) 2,437,340 shares (the &#8220;Shares&#8221;)
of its common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), (ii) 4,756,900 pre-funded warrants (the &#8220;Pre-Funded
Warrants&#8221;) to purchase up to an aggregate of 4,756,900 shares of Common Stock (the &#8220;Pre-Funded Warrant Shares&#8221;) in
lieu of Shares, (iii) 7,194,240 Series A Warrants (the &#8220;Series A Warrants&#8221;) to purchase up to 7,194,240 shares of Common
Stock (the &#8220;Series A Warrant Shares&#8221;) and (iv) 7,194,240 Series B Warrants (the &#8220;Series B Warrants&#8221; and, together
with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 7,194,240 shares of Common Stock (&#8220;the &#8220;Series
B Warrant Shares&#8221; together with the Series A Warrant Shares, the &#8220;Warrant Shares&#8221;). Each Share or Pre-Funded Warrant,
as applicable, was sold together with one Series A Warrant to purchase one share of Common Stock and one Series B Warrant to purchase
one Common Share. Simultaneously with the Closing, the Company closed a private placement offering that involved an existing investor,
which is controlled by a director of the Company, converting approximately $4,093,112 of debt, which represented the then outstanding
principal and accrued interest under an existing secured convertible promissory note on substantially the same terms as the Offering,
resulting in the issuance of 2,640,717 shares of Common Stock (plus 2,640,717 accompanying Series A Common Warrants and 2,640,717 accompanying
Series B Common Warrants) (the Concurrent Private Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of Common Warrant Shares upon exercise of the Common Warrants is subject to stockholder approval under applicable rules and
regulations of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) (&#8220;Stockholder Approval&#8221;, and such proposal to be presented
at the Special Meeting (as defined below), the &#8220;Issuance Proposal&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to hold a meeting to obtain Stockholder Approval (the &#8220;Special Meeting&#8221;) within 60 days following the closing
of the Offering. In connection with the Offering, certain existing Company stockholders entered into support agreements (each a &#8220;Support
Agreement&#8221;) with the Company, pursuant to which certain existing Company stockholders agreed to vote their shares of Common Stock
at the Special Meeting (i) to approve the Issuance Proposal, (ii) to approve the Concurrent Private Offering and the issuance of Common
Stock underlying the Common Warrants sold in the Concurrent Private Offering, and (iii) to approve a reverse stock split of the Company&#8217;s
Common Stock at ratio of between to 1-for-2 and 1-for-20, with such ratio to be determined at the sole discretion of the board of directors
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Support Agreement is qualified in its entirety by reference to the full text of the form of Support Agreement,
a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K includes &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the
United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the
use of words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221;
&#8220;assumes,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;seeks,&#8221; or other similar expressions.
Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including
but not limited to Nasdaq&#8217;s determination as to whether the Company is able to obtain Stockholder Approval and those other risks
under &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission
on March 28, 2024, and the Company&#8217;s Quarterly Reports on Form 10-Q filed on May 15, 2024, August 13, 2024, and November 14, 2024.
Most of these factors are outside the Company&#8217;s control and are difficult to predict. The Company cautions readers not to place
undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any
obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its
expectations or any change in events, conditions or circumstances on which any such statement is based.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: #CCEEFF">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Support Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 18, 2024</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Paul
    Goode</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Goode</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5FmuCgvTToiJWkSLib7SrBNts2cRaj+QtTVvEZWFZZt6MECOxppUpkeG8yDM4YlWX2iPkeENGe8XgSDfbBMLN8W6cZ219//7AlAKDgZmN1fQShN7aGIdFAlLGch6rKUiVKAmHnYg6PSV7MwVab3QJ2hZwYKrZoNf8HhKOuiVL1buvOiE7QzbEjSeD/AE1kQr21OgX8cNBlqUiGvUTiTXTsw6uZevRdiQsS6xCnRvo/0ZfBpJKjA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDER
SUPPORT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>SUPPORT AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;) is made as of November , 2024, by and among Glucotrack, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and the person or persons set forth on the signature page hereto (&ldquo;<U>Stockholder</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company intends to enter into that certain securities purchase agreement, dated November 14, 2024, by and between the Company and
institutional investors (the &ldquo;<U>Purchase Agreement</U>&rdquo;), substantially in the form attached hereto at <U>Exhibit A</U>,
with certain investors in connection with a registered direct offering (the &ldquo;<U>Offering</U>&rdquo;) for the offer and sale of
shares of common stock, par value $0.001 per share (&ldquo;<U>Common Stock</U>&rdquo;) or Pre-Funded Warrants to purchase shares of Common
Stock in lieu of Common Stock, together with Series A common warrants (the &ldquo;<U>Series A Warrants</U>&rdquo;) to purchase Common
Stock (the &ldquo;<U>Series A Warrant Shares</U>&rdquo;) and Series B common warrants (the &ldquo;<U>Series B Warrants</U>&rdquo; and,
together with the Series A Warrants, the &ldquo;<U>Common Warrants</U>&rdquo;) to purchase shares of Common Stock (the &ldquo;<U>Series
B Warrant Shares</U>&rdquo; and, together with the Series A Warrant Shares, the &ldquo;<U>Common Warrant Shares</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company&rsquo;s Common Stock is listed on the Nasdaq Capital Market, and in accordance with Rule 5635(d) of The Nasdaq Stock Market
LLC (&ldquo;<U>Nasdaq</U>&rdquo;), stockholder approval (the &ldquo;<U>Required Stockholder Approval</U>&rdquo;) is required prior to
the issuance of securities in connection with a transaction other than a public offering involving the sale, issuance or potential issuance
of common stock (or securities convertible into or exercisable for common stock) in an amount equal to 20% or more of the common stock
or 20% or more of the voting power outstanding before the issuance at a price less than the &ldquo;Minimum Price.&rdquo; The Minimum
Price is defined as the lower of (i) the closing price of the common stock immediately preceding the signing of the binding agreement
or (ii) the average closing price of the common stock for the five trading days immediately preceding the signing of the binding agreement;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the exercise of the Common Warrants would result in the issuance of a number of Common Warrant Shares equal to 20% or more of the Common
Stock of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
in order to receive the Required Stockholder Approval, the board of directors of the Company (the &ldquo;<U>Board</U>&rdquo;) has determined
to call a special meeting of the stockholders of the Company (the &ldquo;<U>Special Meeting</U>&rdquo;) to hold a vote of the Company&rsquo;s
stockholders to approve a proposal generally stating, &ldquo;A proposal to approve the issuance, in accordance with Nasdaq Rule 5635(d),
of 20% or more of our Common Stock including the issuance of the Common Warrants and subject to the terms of the Common Warrants, any
resulting issuance of Common Warrant Shares, pursuant to the Purchase Agreement&rdquo;(the &ldquo;<U>Issuance Proposal</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
on August 5, 2024, the Company was granted an extension by the Listing Qualifications Staff of Nasdaq to regain compliance with Nasdaq
Listing Rule 5550(a)(2) (the &ldquo;<U>Bid Price Rule</U>&rdquo;), requiring the Company to maintain a closing minimum bid price of $1.00
per share of its Common Stock for 30 consecutive business days (the &ldquo;<U>Minimum Bid Price Requirement</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Board believes that, in order to maintain listing on the Nasdaq Capital Market and regain compliance with the Minimum Bid Price Requirement,
the Company&rsquo;s should enact a reverse stock split of the Company&rsquo;s issued and outstanding shares of Common Stock at a ratio
of between to 1-for-2 and 1-for-20, and has determined to ask the stockholders of the Company at the Special Meeting to vote on a proposal
generally stating &ldquo;A proposal to approve an amendment to the Company&rsquo;s Certificate of Incorporation to effect a reverse stock
split of the Company&rsquo;s common stock, par value $0.001 per share, at a ratio of between to 1-for-2 and 1-for-20, with such ratio
to be determined at the sole discretion of the Board (the &ldquo;Reverse Stock Split&rdquo;) and with such Reverse Stock Split to be
effected at such time and date, if at all, as determined by the Board in its sole discretion&rdquo; (the &ldquo;<U>Reverse Stock Split
Proposal</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company entered into a convertible promissory note with an investor who is also a director of the Company (the &ldquo;<U>Investor</U>&rdquo;),
in the aggregate principal amount of $4,000,000 (the &ldquo;<U>July 30 Note</U>&rdquo;). The Investor, in a private placement offering
(the &ldquo;<U>Concurrent Private Offering</U>&rdquo;) will voluntarily convert approximately $4,093,112 of debt, representing the outstanding
principal and accrued interest of the July 30 Note as of the date the Purchase Agreement is executed (the &ldquo;<U>Debt</U>&rdquo;),
resulting in an issuance of a number of shares of Common Stock (plus accompanying Series A Warrants and Series B Warrants) equal to the
Debt, divided by the offering price of a share of Common Stock and accompanying Common Warrants in the Offering (the &ldquo;<U>Conversion
Price</U>&rdquo;); <I>provided that</I> the Conversion Price shall not be lower than the &ldquo;Market Value,&rdquo; which means the
consolidated closing bid price immediately preceding the time the Company enters into a binding agreement to issue the securities (the
&ldquo;<U>Concurrent Issuances</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Board has determined to ask the stockholders of the Company at the Special Meeting to approve the Concurrent Private Offering and
the Concurrent Issuances (the &ldquo;<U>Concurrent Offering and Issuance Proposal</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
as of the date hereof, each Stockholder owns of record the number of shares of Common Stock set forth on such Stockholder&rsquo;s signature
page hereto (all such Common Stock held by each such Stockholder as of the date of this Agreement and any Common Stock of which ownership
of record or the power to vote is hereafter acquired by the Stockholders prior to the termination of this Agreement being referred to
herein collectively as the &ldquo;<U>Shares</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, each Stockholder, severally and not jointly, hereby agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Agreement to Vote</U>. Each Stockholder, by this Agreement, with respect to its Shares, severally and not jointly, hereby agrees (and
agrees to execute such documents or certificates effectuating such agreement as the Company may reasonably request in connection therewith)
to vote, at any meeting of the Company Stockholders, and in any action by written consent of the Company Stockholders, all of such Stockholder&rsquo;s
Shares (a) in favor of the Issuance Proposal, (b) in favor of the Reverse Stock Split Proposal, (c) in favor of the Concurrent Offering
and Issuance Proposal and (d) in favor of any other matter reasonably necessary to obtain the Required Stockholder Approval and considered
and voted upon by the Company Stockholders. Each Stockholder acknowledges receipt and review of a copy of the Purchase Agreement. Except
as expressly set forth in this Section 1, nothing in this Agreement shall limit the right of each Stockholder to vote (including by proxy
or written consent, if applicable) in favor of, against or abstain with respect to any matters presented to the Company Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Transfer of Shares</U>. Absent the prior written consent of the Company (which may be granted or withheld in the Company&rsquo;s sole
discretion), each Stockholder severally and not jointly, agrees that it shall not, directly or indirectly, (a) sell, assign, transfer
(other than by operation of law), gift, lien, pledge, hypothecate, dispose of or otherwise encumber any of the Shares or otherwise agree
to do any of the foregoing, (b) deposit any Shares into a voting trust or enter into a voting agreement or arrangement or grant any proxy
or power of attorney with respect thereto that is inconsistent with this Agreement, (c) enter into any contract, option or other arrangement
or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (other than by operation of law), gift
or other disposition of any Shares, or (d) take any action that would make any representation or warranty of such Stockholder herein
untrue or incorrect in any respect or have the effect of preventing or disabling the Stockholder from performing its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>No Solicitation.</U> Each Shareholder severally and not jointly, agrees that it will not, and will not knowingly permit any entity
under its control to, directly or indirectly, through any officer, director, representative, agent or otherwise, solicit, initiate or
knowingly encourage (including by furnishing information) the submission of, or participate in any discussions or negotiations regarding
any transaction that would be detrimental to the Issuance Proposal, the Reverse Stock Split Proposal, the Concurrent Offering and Issuance
Proposal or the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>No Proxy Solicitations</U>. Each Stockholder severally and not jointly, agrees that it will not, and will not permit any entity under
the Stockholder&rsquo;s control to, directly or indirectly, through any officer, director, representative, agent or otherwise, (a) solicit
proxies or become a participant in a solicitation in opposition to the Issuance Proposal, the Reverse Stock Split Proposal or the Concurrent
Offering and Issuance Proposal, (b) grant any proxy, power of attorney or other right to vote the Shares, except for proxies or voting
instructions to vote such Shares in accordance with Section 1 hereof, (c) assist any person, entity or group in taking or planning any
action that would or could reasonably be expected to compete with, restrain, materially delay the approval of the Issuance Proposal,
the Reverse Stock Split Proposal or the Concurrent Offering and Issuance Proposal or (d) act jointly or in concert with others with respect
to voting securities of the Company for the purpose of opposing or competing with the Company or its affiliates in connection with the
approval of the Issuance Proposal, the Reverse Stock Split Proposal or the Concurrent Offering and Issuance Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Representations and Warranties</U>. Each Stockholder severally and not jointly, represents and warrants to the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The execution, delivery and performance by such Stockholder of this Agreement and the consummation by such Stockholder of the transactions
contemplated hereby do not and will not (i) conflict with or violate any United States or non-United States Law applicable to such Stockholder,
(ii) require any consent, approval or authorization of, declaration, filing or registration with, or notice to, any person or entity
(except for filings with the SEC by such Stockholder or as would not impact Stockholder&rsquo;s ability to perform or comply with its
obligations under this Agreement in any material respect), (iii) result in the creation of any encumbrance on any Shares (other than
pursuant to this Agreement) or (iv) if applicable, conflict with or result in a breach of or constitute a default under any provision
of such Stockholder&rsquo;s governing documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Such Stockholder owns exclusively, beneficially and of record and has good, valid and marketable title to the Shares set forth on such
Stockholder&rsquo;s signature page hereto free and clear of any security interest, lien, claim, pledge, hypothecate, proxy, option, right
of first refusal, agreement, voting restriction, limitation on disposition, charge, adverse claim of ownership or use or other encumbrance
of any kind, other than pursuant to (i) this Agreement, (ii) applicable securities laws or (iii) as specifically disclosed on such Stockholder&rsquo;s
signature page hereto, and has, except as specifically disclosed on such Stockholder&rsquo;s signature page hereto, the sole power (as
currently in effect) to vote and full right, power and authority to sell, transfer and deliver such Shares, and such Stockholder does
not own, directly or indirectly, any other Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Such Stockholder has the power, authority and capacity to execute, deliver and perform this Agreement and that this Agreement has been
duly authorized, executed and delivered by such Stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Termination</U>. This Agreement and the obligations of the Stockholders under this Agreement shall automatically terminate upon the
earliest of (i) the termination of the Offering and (ii) the date on which the Company obtains the Required Stockholder Approval. Nothing
in this Section 6 shall relieve any party of liability for fraud or willful breach of this Agreement occurring prior to termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed
to have been duly given upon receipt) by delivery in person, by e-mail or by registered or certified mail (postage prepaid, return receipt
requested) to the respective parties at the following addresses or e-mail addresses (or at such other address or email address for a
party as shall be specified in a notice given in accordance with this Section 6(a)):</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company, to it at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucotrack,
Inc..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">301
Rte. 17 North, Ste. 800,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rutherford,
NJ 07070</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Paul Goode</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
pvgoode@glucotrack.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Mannheim, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson
Mullins Riley &amp; Scarborough LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">301
Hillsborough Street, Suite 1400</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raleigh,
NC 27603</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
david.mannheim@nelsonmullins.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to a Stockholder, to the address or email address set forth for Stockholder on the signature page hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy,
all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior
agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof. This
Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise), except that the Company may assign
all or any of its rights and obligations hereunder to any affiliate of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
This Agreement shall be binding upon and inure solely to the benefit of each party hereto (and the Company&rsquo;s permitted assigns),
and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy
of any nature whatsoever under or by reason of this Agreement. No Stockholder shall be liable for the breach by any other Stockholder
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The parties hereto agree that irreparable damage would occur in the event any provision of this Agreement was not performed in accordance
with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy
at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to contracts executed
in and to be performed in that State. All actions arising out of or relating to this Agreement shall be heard and determined exclusively
in any Delaware Chancery Court. The parties hereto hereby (i) submit to the exclusive jurisdiction of the Delaware Chancery Court for
the purpose of any action arising out of or relating to this Agreement brought by any party hereto, and (ii) irrevocably waive, and agree
not to assert by way of motion, defense, or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction
of the above-named courts, that its property is exempt or immune from attachment or execution, that the action is brought in an inconvenient
forum, that the venue of the action is improper, or that this Agreement or the transactions contemplated hereunder may not be enforced
in or by any of the above-named courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The words &ldquo;hereof&rdquo;, &ldquo;herein&rdquo;, and &ldquo;hereunder&rdquo; and words of similar import, when used in this Agreement,
shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (b) the words &ldquo;date hereof,&rdquo;
when used in this Agreement, shall refer to the date set forth in the Preamble; (c) the terms defined in the singular have a comparable
meaning when used in the plural, and vice versa; (d) the terms defined in the present tense have a comparable meaning when used in the
past tense, and vice versa; (e) any references herein to a specific Section or Article shall refer, respectively, to Sections or Articles
of this Agreement; (f) references herein to any gender (including the neuter gender) includes each other gender; (g) the word &ldquo;or&rdquo;
shall not be exclusive; (h) the headings herein are for convenience of reference only, do not constitute part of this Agreement and shall
not be deemed to limit or otherwise affect any of the provisions hereof; and (i) the parties hereto have participated jointly in the
negotiation and drafting of this Agreement and, in the event that an ambiguity or question of intent or interpretation arises, this Agreement
shall be construed as jointly drafted by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
This Agreement may be executed and delivered (including by facsimile or portable document format (pdf) transmission) in one or more counterparts,
and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of
which taken together shall constitute one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
This Agreement is intended to create, and creates, a contractual relationship and is not intended to create, and does not create, any
agency, partnership, joint venture or any like relationship between the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
This Agreement is not intended to confer upon any Person other than the parties hereto any rights or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Each of the parties hereto hereby waives to the fullest extent permitted by applicable law any right it may have to a trial by jury with
respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement. Each of the parties hereto
(i) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party
would not, in the event of litigation, seek to enforce that foregoing waiver and (ii) acknowledges that it and the other parties hereto
have been induced to enter into this Agreement and the transactions contemplated hereby, as applicable, by, among other things, the mutual
waivers and certifications in this paragraph (k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
pages follow]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-transform: uppercase"><B>Glucotrack,
    Inc.</B></FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>[stockholder]</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Shares:</FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECURITIES PURCHASE AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is entered into and made effective as of November , 2024, between
Glucotrack, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto
(each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) as to the Shares, the Pre-Funded Warrants, the Series A Warrants, and
the Series B Warrants (each as defined herein) (collectively, the &ldquo;<U>Securities</U>&rdquo;), the Company desires to issue and
sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, the Securities of the Company
as provided in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
words and terms have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>BHCA</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>BSA/PATRIOT
Act</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.2(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to <U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2nd) Trading Day following the date hereof if this Agreement is signed on a day that is
not a Trading Day or after 4:00 p.m. (New York, NY time) and before midnight (New York, NY time) on a Trading Day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time shares of Common Stock, including, without limitation, any debt, preferred shares, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares
of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Nelson Mullins Riley &amp; Scarborough LLP, counsel to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Control</U>&rdquo;
(including the terms &ldquo;<U>Controlled by</U>&rdquo; and &ldquo;<U>under common Control with</U>&rdquo;) means the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership
of voting securities, as trustee or executor, by contract or otherwise, including the ownership, directly or indirectly, of securities
having the power to elect a majority of the board of directors or similar body governing the affairs of such person or securities that
represent a majority of the outstanding voting securities of such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York, NY time) and
before midnight (New York, NY time) on any Trading Day, 9:01 a.m. (New York, NY time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York, NY time) and 9:00 a.m. (New York, NY time) on any Trading Day, no later than 9:01 a.m. (New York, NY time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DVP</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DWAC</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 2.2(a)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EDGAR</U>&rdquo;
means the Electronic Data Gathering, Analysis, and Retrieval System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>ERISA</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.2(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (i) shares of Common Stock, restricted stock units, or options, including the shares of Common
Stock underlying the restricted stock units or options, to employees, officers, directors, or consultants of the Company pursuant to
any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (ii) Common
Stock issued upon the exercise or exchange of or conversion of any Warrants issued hereunder or Common Stock Purchase Warrants issued
to the Placement Agent in connection with the Offering and/or other securities exercisable or exchangeable for or convertible into shares
of Common Stock issued and outstanding on the date of this Agreement <I>provided</I> that such securities have not been amended since
the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price, or conversion
price of such securities (other than in connection with stock splits or combinations or anti-dilution provisions contained therein as
disclosed in the SEC Reports and the Prospectus) or to extend the term of such securities or securities issuable in connection with a
transaction involving the Company and existing stockholders in which the Company offers the existing stockholders the option to exchange
their shares of Common Stock for other securities of the Company, (iii), securities issued pursuant to merger, acquisition, or strategic
transactions approved by a majority of the disinterested directors of the Company, <I>provided</I> that such securities are issued as
&ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any
registration statement in connection therewith during the prohibition period in <U>Section 4.11(a)</U> herein, and <I>provided</I>, <I>further
</I>that any such issuance shall only be to a Person that (or to the equity holders of a Person) which is, itself or through its subsidiaries,
an operating company, or an owner of an asset in a business synergistic with the business of the Company and in which the Company receives
benefits in addition to any investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities, (iv) securities for settlement
of outstanding payables or liabilities <I>provided</I> that such securities are issued as &ldquo;restricted securities&rdquo; (as defined
in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
during the prohibition period in <U>Section 4.11(a)</U> herein, and (v) up to $8,000,000 of securities issued to other purchasers pursuant
to the Prospectus concurrently with the Closing at the Per Share Purchase Price, less the aggregate Subscription Amount pursuant to this
Agreement, and the Placement Agent&rsquo;s Warrants pursuant to the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(l)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(ll)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Federal
Reserve</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 2.2(a)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Food
and Drug Regulations</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(ll)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FTC</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(l)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(h)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GDPR</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(oo)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(z)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>IT
Systems and Data</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(nn)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(o)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Placement Agent and the directors, officers,
and 5% stockholders of the Company, substantially in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in <U>Section 3.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(n)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Misconduct</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(k)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Money
Laundering Laws</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(jj)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Non-cooperative
Jurisdiction</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.2(j)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>OFAC</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(gg)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Offering</U>&rdquo;
shall mean the offering of the Securities contemplated by this Agreement and the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $1.39, subject to adjustment for reverse and forward share splits, share dividends, share combinations
and other similar events with respect to shares of Common Stock that occur after the date of this Agreement and prior to the Closing;
<I>provided</I> that the purchase price per Pre-Funded Warrant shall be the Per Share Purchase Price minus $0.001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint share company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Personal
Data</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(oo)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agency Agreement</U>&rdquo; means the Placement Agency Agreement by and between the Company and the Placement Agent dated as of November
12, 2024, as it may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Dawson James Securities, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Policies</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(oo)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means the Common Stock Purchase Warrants delivered to certain of the Purchasers at the Closing in accordance with
Section 2.2(a)(ix) hereof to the extent any Purchasers elect to receive Pre-Funded Warrants in lieu of Shares, which Pre-Funded Warrants
shall be exercisable into shares of Common Stock and shall be in the form of <U>Exhibit B</U> attached hereto, which Pre-Funded Warrants
shall be exercisable beginning on the Initial Exercise Date (as defined therein) until all of the Pre-Funded Warrants have been exercised,
and shall be exercisable at an exercise price of $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means the preliminary prospectus dated November 12, 2024, filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Settlement
Period</U>&rdquo; shall have the meaning set forth in <U>Section 5.21</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Settlement
Shares</U>&rdquo; shall have the meaning set forth in <U>Section 5.21</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Privacy
Laws</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(oo)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, a preliminary inquiry, an informal investigation
or a partial proceeding, such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Product</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(ll)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 4.8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form S-1 filed with SEC (File No. 333-282158) which registers the
sale of the Securities to the Purchasers, and shall include the Rule 462(b) Registration Statement if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from
time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such
Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from
time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such
Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
462(b) Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities,
which was filed with the SEC on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by
the SEC pursuant to the Securities Act, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC</U>&rdquo;
means the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares and the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
A Warrants</U>&rdquo; means the Common Stock Purchase Warrants delivered to the Purchasers at the Closing in accordance with Section
2.2(a)(viii) hereof, which Series A Warrants shall be exercisable into shares of Common Stock and shall be in the form of <U>Exhibit
C</U> attached hereto, which Series A Warrants shall be exercisable beginning on the Initial Exercise Date (as defined therein), have
a term of five years from the Series A Warrants&rsquo; Initial Exercise Date, and shall be exercisable at an exercise price of $1.81
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
B Warrants</U>&rdquo; means the Common Stock Purchase Warrants delivered to the Purchasers at the Closing in accordance with Section
2.2(a)(ix) hereof, which Series B Warrants shall be exercisable into shares of Common Stock and shall be in the form of <U>Exhibit D
</U>attached hereto, which Series B Warrants shall be exercisable beginning on the Initial Exercise Date (as defined therein), have a
term of two and a half (2.5) years from the Series B Warrants&rsquo; Initial Exercise Date, and shall be exercisable at an exercise price
of $1.81 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shareholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or
any successor entity) from the shareholders of the Company with respect to (i) reduction to the applicable floor price in the Warrants
inapplicable, (ii) adjustment terms in the Warrants, (iii) issuance of all of the Warrant Shares upon the exercise the Warrants in accordance
with their terms (including adjustment provisions set forth therein), and (iv) to consent to any adjustment to the exercise price or
number of shares of Common Stock underlying the Warrants in the event of a Share Combination Event, Dilutive Issuance and Reset Date
(as defined in the Warrants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shareholder
Approval Date</U>&rdquo; means the Trading Day that Shareholder Approval is received and deemed effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock which are issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shell
Bank</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.2(h)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Shares or Pre-Funded Warrants (in lieu of Shares)
and Warrants purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the
heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s
aggregate exercise price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for
cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
of any person means any corporation, partnership, limited liability company, joint stock company, joint venture or other organization
or entity, whether incorporated or unincorporated, which is Controlled by such Person, and shall, where applicable, also include any
direct or indirect subsidiary of the Company formed or acquired after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the shares of Common Stock are listed or quoted for trading
on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange,
or the NYSE American (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Lock-Up Agreements, the Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Vstock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Pl, Woodmere,
NY 11598, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 4.11(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (i) if the shares of Common Stock are then
listed or quoted on a Trading Market, the daily volume weighted average price of a share of Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the shares of Common Stock are then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York, NY time) to 4:02 p.m. (New York, NY time)), (ii) if the OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX, (iii)
if shares of Common Stock are not then listed or quoted for trading on the OTCQB or OTCQX and if prices for shares of Common Stock are
then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to
its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (iv) in all other cases, the
fair market value per share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase,
up to an aggregate of $9,090,000 of the Shares and/or the Pre-Funded Warrants and the corresponding Warrants subscribed for by such Purchaser.
Notwithstanding anything herein to the contrary, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s
Subscription Amount (together with such Purchaser&rsquo;s Affiliates, and any Person acting as a group together with such Purchaser or
any of such Purchaser&rsquo;s Affiliates) would cause such Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed
the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants
in lieu of the Shares as determined pursuant to <U>Section 2.2(a)</U>. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% (or, with respect to each Purchaser, at the election of the Purchaser at Closing, 9.99%) of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of the Shares on the Closing Date. In each case, the election to receive
Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature
page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) settlement
with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, Pre-Funded Warrants, Series A Warrants
and Series B Warrants, as applicable to such Purchaser and as indicated on such Purchaser&rsquo;s signature page hereto and determined
based on its respective Subscription Amount and election for Shares and/or Pre-Funded Warrants, and the Company and each Purchaser shall
deliver the other items set forth in <U>Section 2.2</U> deliverable at the Closing. Upon satisfaction of the covenants and conditions
set forth in <U>Sections 2.2</U> and <U>2.3</U>, the Closing shall occur remotely by electronic transfer of the Transaction Documents
and other items deliverable hereunder. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP
(i.e., on the Closing Date, the Company shall issue the Securities registered in the Purchasers&rsquo; names and addresses, and the Shares
shall be released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt
of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor
shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus, the Company may sell up to $910,000 of
additional Shares or Pre-Funded Warrants in lieu thereof and Warrants to purchasers not party to this Agreement, less the aggregate Subscription
Amount pursuant to this Agreement, and will issue to such purchasers such shares of Common Stock and Warrants or Pre-Funded Warrants
in lieu thereof and Warrants in the same form and at the same Per Share Purchase Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The
Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable upon exercise of such
Purchaser&rsquo;s Pre-Funded Warrant, if applicable), registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
duly executed Pre-Funded Warrants, if any, and Warrants issued and registered in the name of such Purchaser, as applicable to such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a legal opinion of Company Counsel and a legal opinion of the Company&rsquo;s intellectual property counsel, each in a form reasonably
acceptable to the Placement Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
a good standing certificate or its equivalent of the Company and each of its Subsidiaries in each such entity&rsquo;s jurisdiction of
incorporation or formation issued by the relevant competent state or local government authority or registrar of companies or entities
as applicable, dated as of a date within ten (10) days of the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
a certificate executed by the Chief Executive Officer of the Company, in form and substance reasonably satisfactory to the Placement
Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
a certificate executed by the Secretary of the Company, in form and substance reasonably satisfactory to the Placement Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
Lock-up Agreements, in form and substance reasonably acceptable to the Placement Agent, executed by the Company and each officer, director
and greater than five percent (5%) shareholders of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
the Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount (minus, if applicable, a Purchasers aggregate exercise price of the Pre-Funded Warrants, which
amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash), which shall be made available for DVP settlement
with the Company or its designees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to <U>Section 5.21</U> below, as applicable, the obligations of the Company hereunder in connection with the Closing are subject
to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
such representation or warranty is as of a specific date therein in which case they shall be accurate in all material respects (or, to
the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in <U>Section 2.2(b)</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Subject to <U>Section 5.21</U> below, as applicable, the respective obligations of the Purchasers hereunder in connection with the Closing
are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
such representation or warranty is as of a specific date therein in which case they shall be accurate in all material respects (or, to
the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in <U>Section 2.2(a)</U> of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date of this Agreement and to the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
from the date of this Agreement to the Closing Date, trading in the shares of Common Stock shall not have been suspended by the SEC or
any Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not
have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service,
or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
no stop order suspending the effectiveness of the Registration Statement, or any post-effective amendment thereto, has been issued under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to each Purchaser
as of the date hereof and as of the Closing Date (unless as of a specific date therein, in which case they shall be accurate as of such
date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect Subsidiaries of the Company are set forth in the Registration Statement. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and
all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and
free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and, if applicable under the laws of the jurisdiction in which they are formed, in good standing under the laws of the
jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and
to carry on its business as currently conducted. The Company and each of the Subsidiaries has all necessary authorizations, approvals,
orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the date
of this Agreement to conduct its business purpose in all material respects as described in the Registration Statement and SEC Reports
and to own or lease its properties. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its
respective certificate or articles of incorporation or association, bylaws or other organizational or charter documents. Each of the
Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in
each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where
the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a
material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the
results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as
a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); <I>provided</I> that a change
in the market price or trading volume of the Common Stock alone shall not be deemed, in and of itself, to constitute a Material Adverse
Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors, or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation or association, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of
the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar
adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or
other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses
(ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the SEC of the Prospectus, (iii) application(s) to each applicable
Trading Market for the listing of the Shares and the Warrant Shares for trading thereon in the time and manner required thereby, (iv)
such filings as are required to be made under applicable state securities laws, and (v) the filing and mailing of a proxy statement on
Schedule 14A in connection with the Shareholder Approval (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the
applicable Transaction Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed
by the Company. The Warrants are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents,
will constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms.
The Warrant Shares are duly authorized and, when issued in accordance with the terms of the Warrants against payment therefor as provided
therein, will be validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Company has reserved
from its duly authorized capital the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants (without
taking into account any limitations on the exercise of the Warrants set forth therein). The Company has prepared and filed the Registration
Statement in conformity with the requirements of the Securities Act, which became effective on November 12, 2024, including the Prospectus,
and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective
under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Preliminary Prospectus or the Prospectus has been issued by the SEC and no Proceedings for that purpose have
been instituted or, to the knowledge of the Company, are threatened by the SEC. The Company, if required by the rules and regulations
of the SEC, shall file the Prospectus with the SEC pursuant to Rule 424(b). At the time the Registration Statement and any amendments
thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto
conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Preliminary Prospectus, the Prospectus and any amendments or supplements thereto, at the time the Preliminary
Prospectus and the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in
all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
&ldquo;issuer free writing prospectus&rdquo; (as defined in Rule 433 under the Securities Act) relating to the Securities is hereafter
referred to as an &ldquo;<U>Issuer Free Writing Prospectus</U>.&rdquo; Any reference herein to the Preliminary Prospectus and the Prospectus
shall be deemed to refer to and include the documents incorporated by reference therein as of the date of filing thereof; and any reference
herein to any &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to any of the Preliminary Prospectus and the Prospectus
shall be deemed to refer to and include (i) the filing of any document with the Commission incorporated or deemed to be incorporated
therein by reference after the date of filing of such Preliminary Prospectus or Prospectus and (ii) any such document so filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Preliminary Prospectus, the Prospectus, or any Issuer Free Writing Prospectus,
or any amendments or supplements to any of the foregoing, shall be deemed to include any copy thereof filed with the Commission on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on Schedule 3.1(g) which Schedule 3.1(g)
shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date
hereof. The Company has not issued any capital stock or Common Stock Equivalents since its most recently filed periodic report under
the Exchange Act, other than pursuant to the exercise of employee stock options or vesting and settlement of restricted stock units under
the Company&rsquo;s stock option or equity incentive plans, the issuance of shares of Common Stock to employees pursuant to any employee
stock purchase plans, and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most
recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase
and sale of the Securities and set forth on Schedule 3.1(g), there are no outstanding options, warrants, scrip rights to subscribe to,
calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or
exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or Common Stock Equivalents
or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The
issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or Common Stock Equivalents
or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any
Subsidiary with any provision that adjusts, and the issuance and sale of the Securities will not result in a right of any holder of Company
securities or instruments to adjust, the exercise, conversion, exchange or reset price under any of such securities or instruments upon
an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any
Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does
not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the
outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued
in compliance with all federal and state securities laws where applicable, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval
or authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of the Securities. There
are no shareholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which
the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof and the
registration statement on Form S-1 (File No. 333-282158), for the one (1) year preceding the date of this Agreement (or such shorter
period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto
and documents incorporated by reference therein, together with the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC
Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior
to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i)
under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis
during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material
respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
The selected financial data set forth under the caption &ldquo;Selected Financial Data&rdquo; in the SEC Reports fairly present, on the
basis stated in such SEC Reports, the information included therein. The agreements and documents described in the Registration Statement
and the SEC Reports conform in all material aspects to the descriptions thereof contained therein and there are no agreements or other
documents required by the Securities Act and the rules and regulations thereunder to be described in the Registration Statement, the
Prospectus or the SEC Reports or to be filed with the SEC as exhibits to the Registration Statement, that have not been so described
or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or
may be bound or affected and (i) that is referred to in the Registration Statement or the SEC Reports, or (ii) is material to the Company&rsquo;s
business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable
against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x) as such
enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally,
(y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and
(z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses
and to the discretion of the court before which any proceeding therefore may be brought. None of such agreements or instruments has been
assigned by the Company, and neither the Company nor, to the best of the Company&rsquo;s knowledge, any other party is in default thereunder
and, to the best of the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both,
would constitute a default thereunder. To the Company&rsquo;s knowledge, performance by the Company of the material provisions of such
agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree
of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses, including,
without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth in Schedule 3.1(i), (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the SEC, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option or equity incentive plans. The Company does not have pending before the SEC any request for confidential
treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in Schedule 3.1(i),
no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist
with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial
condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least one Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. There is no Proceeding pending or, to the knowledge of the Company, threatened against or affecting the Company, any
Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) which (i) adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected
to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the
subject of any Proceeding involving a claim of violation of or liability under federal or state securities laws or a claim of breach
of fiduciary duty, which could result in a Material Adverse Effect. There has not been, and to the knowledge of the Company, there is
not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer of the Company.
The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company
or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. (1) No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. (2) No executive officer of the Company or any Subsidiary, to the knowledge of
the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in
favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries
to any liability with respect to any of the foregoing matters. (3) To the Company&rsquo;s knowledge, (a) no allegation of sexual harassment,
sexual misconduct or discrimination, whether such discrimination arises from race, ethnic background, sex, gender status, age or otherwise
(&ldquo;<U>Misconduct</U>&rdquo;) have been made involving any current or former director, officer, employee or independent contractor
of the Company or any of its Subsidiaries, (b) neither the Company nor any of its Subsidiaries have entered into any settlement agreements
related to allegations of Misconduct by any current or former director, officer, employee, or independent contractor of the Company or
any of its Subsidiaries. (4) The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to the U.S. Food and Drug Administration
(&ldquo;<U>FDA</U>&rdquo;) and comparable foreign regulators, the U.S. Federal Trade Commission (&ldquo;<U>FTC</U>&rdquo;), state unfair
trade practice laws and rules and foreign equivalents, taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of Proceedings relating to the revocation or
modification of any Material Permit. The disclosures in the Registration Statement concerning the effects of federal, state, local and
all foreign regulation on the Company&rsquo;s business as currently contemplated are correct in all material respects. The Company is
and has been in material compliance with any term of any such Material Permits, except for any violations which would not reasonably
be expected to have a Material Adverse Effect. The Company has not received notice of any Proceeding from any governmental authority
or third party alleging that any product, operation or activity is in violation of any applicable laws or regulations or Material Permits
or has any knowledge that any such entity or third party is considering any such Proceeding, nor, to the Company&rsquo;s knowledge, has
there been any material noncompliance with or violation of any applicable laws or regulations by the Company that could reasonably be
expected to require the issuance of any such communication or result in an investigation, corrective action, or enforcement action by
any governmental authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all
material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary
has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim
or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could
not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company
and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in Schedule 3.1(q), none of the executive officers or directors
of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, executive officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to
or from any executive officer, director or such employee or, to the knowledge of the Company, any entity in which any executive officer,
director, or any such employee has a substantial interest or is an officer, director, trustee, shareholder, member or partner, in , in
each case in excess of 1% of the Company&rsquo;s average total assets as of December 31, 2023 and 2022 other than for: (i) payment of
salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee
benefits, including equity award or option agreements under any equity incentive plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date of this Agreement and applicable to the Company and
the Subsidiaries, and any and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date
of this Agreement and as of the Closing Date and applicable to the Company and the Subsidiaries. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the Company&rsquo;s disclosure controls
and procedures of the Company and the Subsidiaries as of the end of the period covered by the Company&rsquo;s most recently filed periodic
report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed
periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal
control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Certain Fees</U>. Except as set forth in the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or
other Person with respect to the transactions contemplated by the Transaction Documents. Other than for Persons directly engaged by a
Purchaser, if any, the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf
of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by
the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Registration Rights</U>. Other than the selling stockholders listed in the resale prospectus of the Registration Statement, no Person
has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Listing and Maintenance Requirements</U>. The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the shares of Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating
such registration. The Company has not, in the twelve (12) months preceding the date of this Agreement, received notice from any Trading
Market on which the shares of Common Stock are or have been listed or quoted to the effect that the Company is not in compliance with
the listing or maintenance requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through
the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository
Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its jurisdiction of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the
Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result
of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding
the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is true and correct in all material
respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by
the Company during the 12 months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes
or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this Offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Solvency</U>. Except as disclosed in the Preliminary Prospectus or the Prospectus, based on the consolidated financial condition of
the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities
hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount that will be required to be paid on or in respect
of the Company&rsquo;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&rsquo;s
assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including
its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and
projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds
the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would
be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not
intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). Except as disclosed in the Preliminary Prospectus or the Prospectus, the Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one (1) year from the Closing Date. The Preliminary Prospectus and the Prospectus sets forth as of the
date of this Agreement and as of the Closing Date, respectively, all outstanding secured and unsecured Indebtedness of the Company or
any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of Fifty Thousand Dollars ($50,000) (other than trade accounts
payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of
indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the
notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary
course of business; and (z) the present value of any lease payments in excess of One Hundred Thousand Dollars ($100,000) due under leases
required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and franchise taxes and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which
it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment
of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any
Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA. The Company
has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all
material respects with the FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Accountants</U>. The Company&rsquo;s independent registered public accounting firm is set forth in the Preliminary Prospectus and
the Prospectus. To the knowledge of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange
Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for
the fiscal year ending December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgement Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
shares of Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length
counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers
may engage in hedging activities at various times during the period that the Securities are outstanding, and (z) such hedging activities
(if any) could reduce the value of the existing shareholders&rsquo; equity interests in the Company at and after the time that the hedging
activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any
of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf (other than the Placement Agent,
as to which no representation is made) has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid
for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person
any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and
(iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or Affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable United States federal and state and foreign money laundering statutes and applicable rules and regulations thereunder (collectively,
the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Proceeding by or before any court or governmental agency, authority or body or
any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the
Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Food and Drug Regulations</U>. As to each product subject to the jurisdiction of the FDA under the Federal Food, Drug and Cosmetic
Act, and the regulations thereunder (the &ldquo;<U>FDCA</U>&rdquo;) and similar or comparable governmental authorities located in other
countries and laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application
approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising,
record keeping and filing of reports, including, without limitation in foreign jurisdictions including Health Canada (collectively, &ldquo;<U>Food
and Drug Regulations</U>&rdquo;), that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company
or any of its Subsidiaries (each such product, a &ldquo;<U>Product</U>&rdquo;), such Product is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under applicable Food and Drug
Regulations, except where the failure to be in compliance would not have or would reasonably be expected to have a Material Adverse Effect
or as is disclosed in the Preliminary Prospectus or the Prospectus. Except as disclosed in the Preliminary Prospectus or the Prospectus,
there is no pending, completed or, to the Company&rsquo;s knowledge, threatened, Proceeding against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication arising from or relating
to Food and Drug Regulations, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Product, (ii) withdraws its
approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional
materials relating to, any Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree
of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its Subsidiaries (including Food and Drug Regulations), and which, either individually or in the aggregate,
would have or would reasonably be expected to have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable Food and Drug Regulations. The Company has
not been informed by the FDA or any other governmental authority that such governmental authority will prohibit the marketing, sale,
license or use in the United States or in another jurisdiction of any product proposed to be developed, produced or marketed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options or awards prior to, or otherwise knowingly coordinate the grant of stock options
or awards with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial
results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Cybersecurity</U>. There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems
and Data</U>&rdquo;) that would reasonably be expected to result in, individually or in the aggregate, a Material Adverse Effect and
(i) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any material security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries
are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented
and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and
disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last three (3) years
were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations, including,
without limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the FTC, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR; and (iv) any other piece
of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of
any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures made or contained
in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the execution, delivery
and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither the Company nor the
Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability of the Company or
the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws; (ii) is currently
conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any regulatory request
or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any court or arbitrator or governmental
or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date of this Agreement and as of the Closing Date to the Company as follows (unless as of a specific date therein,
in which case they shall be accurate as of such date):</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7) or (a)(8), (a)(9), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule
144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto), and the SEC Reports including the Prospectus and, has been afforded, (i) the opportunity to ask
such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company
and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable
effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges
and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information
or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any
Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate
may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection
with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial
advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Ownership of Company Securities</U>. Except as disclosed in writing to the Company as of the date of this Agreement, no Purchaser,
any of its Affiliates, or any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Purchaser&rsquo;s
for purposes of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, including any &ldquo;group&rdquo;
of which the Purchaser is a member, directly or indirectly owns, beneficially or otherwise (including solely with respect to an economic
interest), any of the outstanding shares of Common Stock, or any other shares of capital stock, options, warrants, derivative securities,
rights or any other securities (including any securities convertible into, exchangeable for or that represent the right to receive securities)
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Nature of Warrants</U>. The Purchaser acknowledges that the Warrants will not be immediately exercisable upon issuance, that the Purchaser
may only exercise the Warrants beginning on the applicable Initial Exercise Date, and that the Warrants shall be subject to the Company
complying with applicable rules and regulations of the Trading Market including those relating to the Shareholder Approval Date (as defined
in the Warrants). The Purchaser further acknowledges that while the Company believes the Warrants are compliant with the rules and regulations
of the Trading Market, neither the Company nor the Placement Agent provide any representation, warranty or guarantee that the Warrants
or, based on the Warrants, the Offering are compliant with such rules and regulations and that the Trading Market may require amendment
to the terms of the Warrants in order to comply with its rules and regulations, and the Purchaser covenants and agrees to reasonably
cooperate with the Company and the Placement Agent in good faith in connection with any amendment or other action with respect to the
Warrants that may be required by the Trading Market in the event that the Warrants are deemed to be non-compliant with such rules and
regulations by the Trading Market. The Purchaser further acknowledges that the Warrants will not be listed or quoted for trading on any
securities exchange or quotation system and will not be publicly traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Sanctioned Persons; BSA/PATRIOT Act</U>. Purchaser is not owned or controlled by or acting on behalf of (in connection with this Agreement),
a Sanctioned Person. Purchaser is not an institution that accepts currency for deposit and that (i) has no physical presence in the jurisdiction
in which it is incorporated or in which it is operating and (ii) is unaffiliated with a regulated financial group that is subject to
consolidated supervision (a &ldquo;<U>Shell Bank</U>&rdquo;) or providing banking services to a Shell Bank. Purchaser represents that
if it is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.), as amended by the USA PATRIOT Act
of 2001 and its implementing regulations (collectively, the &ldquo;<U>BSA/PATRIOT Act</U>&rdquo;), that Purchaser maintains policies
and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. Purchaser also represents that, to
the extent required by applicable law, it maintains, either directly or through the use of a third-party administrator, policies, and
procedures reasonably designed for the screening of any investors in the Purchaser against Sanctions-related lists of blocked or restricted
persons. Purchaser further represents and warrants that (A) the funds held by Purchaser and used to purchase the Securities were not
directly or indirectly derived from or related to any activities that may contravene U.S. federal, state, or non-U.S. anti-money laundering,
anti-corruption, or Sanctions laws and regulations or activities that may otherwise be deemed criminal and (B) any returns from the Purchaser&rsquo;s
investment will not be used to finance any illegal activities. For purposes of this Agreement, &ldquo;<U>Sanctioned Person</U>&rdquo;
means at any time any person or entity with whom dealings are restricted, prohibited, or sanctionable under any Sanctions (as defined
below), including as a result of being: (I) listed on any Sanctions-related list of designated or blocked or restricted persons; (II)
that is a national of, the government of, or any agency or instrumentality of the government of, or resident in, or organized under the
laws of, a country or territory that is the target of comprehensive Sanctions from time to time (as of the date of this Agreement, Cuba,
Iran, North Korea, Syria, and the Crimea region); or (III) a relationship of ownership, control, or agency with any of the foregoing.
&ldquo;<U>Sanctions</U>&rdquo; means those trade, economic and financial sanctions laws, regulations, embargoes, and restrictive measures
(in each case having the force of law) administered, enacted, or enforced from time to time by (1) the United States (including without
limitation the U.S. Department of the Treasury, Office of Foreign Assets Control, the U.S. Department of State, and the U.S. Department
of Commerce), (2) the European Union and enforced by its member states, (3) the United Nations, and (4) the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Non-cooperative Jurisdiction</U>. Purchaser is not owned or controlled by or acting on behalf of (in connection with this Agreement),
a person or entity resident in, or whose funds used to purchase the Securities are transferred from or through, a country, territory,
or entity that (i) has been designated as non-cooperative with international anti-money laundering or counter terrorist financing principles
or procedures by the United States or by an intergovernmental group or organization, such as the Financial Action Task Force, of which
the United States is a member; (ii) is the subject of an advisory issued by the Financial Crimes Enforcement Network of the U.S. Department
of the Treasury; or (iii) has been designated by the Secretary of the Treasury under Section 311 of the USA PATRIOT Act as warranting
special measures due to money laundering concerns (any such country or territory, a &ldquo;<U>Non-cooperative Jurisdiction</U>&rdquo;),
or an entity or individual that resides or has a place of business in, or is organized under the laws of, a Non-cooperative Jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>ERISA</U>. If Purchaser is an employee benefit plan that is subject to Title I of the Employee Retirement Income Security Act of 1974,
as amended (&ldquo;<U>ERISA</U>&rdquo;), a plan, an individual retirement account or other arrangement that is subject to section 4975
of the Code or an employee benefit plan that is a governmental plan (as defined in section 3(32) of ERISA), a church plan (as defined
in section 3(33) of ERISA), a non-U.S. plan (as described in section 4(b)(4) of ERISA), or other plan that is not subject to the foregoing
but may be subject to provisions under any other federal, state, local, non-U.S., or other laws or regulations that are similar to such
provisions of ERISA or the Code, or an entity whose underlying assets are considered to include &ldquo;plan assets&rdquo; of any such
plan, account or arrangement subject to the fiduciary or prohibited transaction provisions of ERISA or section 4975 of the Code, Purchaser
represents and warrants that the acquisition and holding of the Securities will not result in a non-exempt prohibited transaction under
ERISA or Section 4975 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Warrant Shares</U>. If all or any portion of the Warrants are exercised at a time when there is an effective registration statement
to cover the issuance or resale of the Warrant Shares or if the Warrants are exercised via cashless exercise, the Warrant Shares issued
pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement
(or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise
available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that
such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is
effective again and available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not
limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal
and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement)
registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired,
the Company covenants to use its reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company
is not then subject to the reporting requirements of the Exchange Act except in the event that the Company consummates: (A) any transaction
or series of related transactions as a result of which any Person (together with its Affiliates) acquires then outstanding securities
of the Company representing more than fifty percent (50%) of the voting control of the Company; (B) a merger or reorganization of the
Company with one or more other entities in which the Company is not the surviving entity; or (C) a sale of all or substantially all of
the assets of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction, other than the Shareholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the SEC within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without
limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective
upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers
or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of such Purchaser,
except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the SEC and (b) to
the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information
and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any
material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that
such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers,
directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall
remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the
SEC on a Current Report on Form 8-K or shall issue a press release containing such material non-public information. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for the purposes set forth in
the Prospectus, and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment
of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any shares of
Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (i) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents, (ii) any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement or Prospectus or by any omission or alleged omission to state therein a material fact necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged
untrue statements in, or omissions or alleged omissions from, information relating to a Purchaser Party furnished in writing by or on
behalf of such Purchaser Party expressly for use in the Registration Statement or Prospectus), or (iii) any Proceeding instituted against
the Purchaser Parties in any capacity (including a Purchaser Party&rsquo;s status as an investor), or any of them or their respective
Affiliates, by the Company or any stockholder of the Company who is not an Affiliate of such Purchaser Party, arising out of or relating
to any of the transactions contemplated by the Transaction Documents. For avoidance of doubt, the indemnification provided herein is
intended to and shall also cover, direct claims brought by the Company against the Purchaser Parties; provided, however, that such indemnification
shall not cover any loss, claim, damage or liability to the extent it is finally judicially determined to be attributable to any Purchaser
Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in any Transaction
Document or any conduct by a Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful
misconduct. If any Proceeding shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this
Agreement, such Purchaser Party shall promptly notify the Company in writing, and, except with respect to direct claims brought by the
Company, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the
Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such Proceeding and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the
employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period
of time to assume such defense and to employ counsel or (iii) in such Proceeding there is, in the reasonable opinion of counsel to the
applicable Purchaser Party (which may be internal counsel), a material conflict on any material issue between the position of the Company
and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser
Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed. In addition, if
any Purchaser Party takes actions to collect amounts due under any Transaction Documents or to enforce the provisions of any Transaction
Documents, then the Company shall pay the cost incurred by such Purchaser Party for such collection, enforcement or action, including,
but not limited to, attorney&rsquo;s fees and disbursements. The indemnification and other payment obligations required by this Section
4.8 shall be made by periodic payments of the amount thereof during the course of the investigation, defense, collection, enforcement
or action, as and when bills are received or are incurred; provided, that if any Purchaser Party is finally judicially determined not
to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the Company for any
payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any cause of action
or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Shares of Common Stock</U>. As of the date of this Agreement, the Company has reserved and the Company shall continue
to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose
of enabling the Company to issue the Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants, including
but not limited to, a number of shares of Common Stock sufficient to honor the issuance of the maximum number of shares of Common Stock
issuable assuming exercise in full of the Series B Warrants via an &ldquo;alternative cashless exercise&rdquo; at the Floor Price (as
defined thereunder) under Section 2(c) of the Series B Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Shares; Shareholder Approval</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing
or quotation of the Shares and Warrant Shares on each Trading Market on which any shares of Common Stock are currently listed, and concurrently
with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Markets and promptly
secure the listing of all of the Shares and Warrant Shares on such Trading Markets. The Company further agrees, if the Company applies
to have the shares of Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and
Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing
and trading of its shares of Common Stock on a Trading Market and will comply in all material respects with the Company&rsquo;s reporting,
filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common
Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer. Notwithstanding the foregoing, this Section 4.10 shall not apply in the event that the Company consummates: (i) any transaction
or series of related transactions as a result of which any Person (together with its Affiliates) acquires then outstanding securities
of the Company representing more than fifty percent (50%) of the voting control of the Company; (ii) a merger or reorganization of the
Company with one or more other entities in which the Company is not the surviving entity; or (iii) a sale of all or substantially all
of the assets of the Company. In addition, the Company shall file a proxy statement on Schedule 14A within ten (10) days of Closing and
hold a special meeting of shareholders (which may also be at the annual meeting of shareholders) at the earliest practical date after
the date following the filing thereof (and in no event later than 60 days after the Closing) for the purpose of obtaining Stockholder
Approval, with the recommendation of the Company&rsquo;s Board of Directors that such proposal be approved, and the Company shall solicit
proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and
all management-appointed proxyholders shall vote their proxies in favor of such proposal. The Company shall provide written notice to
the Purchaser of the anticipated Shareholder Approval Date at least three (3) Trading Days prior to the date of the shareholder meeting
at which the Shareholder Approval is expected to be obtained. The Company shall use its reasonable best efforts to obtain such Stockholder
Approval. In the event the Company fails to obtain Stockholder Approval as contemplated by the terms hereof, each Purchaser shall be
refunded all consideration paid for the Series A Warrants and Series B Warrants purchased by such Purchaser as promptly as practicable
following the Company&rsquo;s failure to obtain such Stockholder Approval, but in any event no later than three (3) Trading Days thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until forty-five (45) days after the Shareholder Approval Date, neither the Company nor any Subsidiary shall (i)
issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents,
or (ii) file any registration statement or amendment or supplement thereto, other than with respect to the Registration Statement or
a registration statement on Form S-8, except for the Securities issued pursuant hereto or otherwise in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until one hundred and eighty (180) days after the Shareholder Approval Date, the Company shall be prohibited from
effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock
Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;Variable Rate Transaction&rdquo; means
a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable
for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate
or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after
the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security (other than in connection with a stock split or
stock dividend or similar event) or upon the occurrence of specified or contingent events directly or indirectly related to the business
of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but
not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price regardless of whether
shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled; provided,
however, that commencing thirty (30) days after the Shareholder Approval Date, the Company&rsquo;s issuance of Common Stock or Common
Stock Equivalents pursuant to an at-the-market facility with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction.
The Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be
in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this <U>Section 4.11</U> shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly, covenants that neither it nor any Affiliate
acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the
Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser,
severally and not jointly, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by
the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the
existence and terms of this transaction. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be
restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agent,
including, without limitation, the Placement Agent after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants sets forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Lock-Up Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its reasonable efforts
to seek specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party hereto to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (i) the time of transmission, if such notice or communication is
delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached
hereto at or prior to 5:30 p.m. (New York, NY time) on a Trading Day, (ii) the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York, NY time) on any Trading Day, (iii)
the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon
actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
with the SEC pursuant to a Current Report on Form 8-K or by issuing a press release containing such material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on
the Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party
against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>Third-Party Beneficiaries</U>. The Placement Agent shall be a third-party beneficiary of the representations and warranties of the
Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit
of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such Proceeding is improper or is an inconvenient venue for such Proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.8, the prevailing party in such Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities for
the applicable statute of limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature
page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of an Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently (if such shares were delivered to the applicable Purchaser) with the return to such Purchaser of the aggregate
exercise price paid to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant
to such Purchaser&rsquo;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Proceeding for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the
convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood
and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward share splits, share dividends, share combinations and other similar events with respect to the shares of Common Stock and
Warrants that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<U>Sales During Pre-Settlement Period</U>. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution
of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to a Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of any Shares to be issued hereunder to such Purchaser at
the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, and the Company shall
be deemed unconditionally bound to sell, such Pre-Settlement Shares to such Purchaser at the Closing; provided, that the Company shall
not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt of the purchase price of
such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not
constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall
sell any Shares to any Person and that any such decision to sell any Shares by such Purchaser shall be made, in the sole discretion of
such Purchaser, at the time such Purchaser elects to effect any such sale, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.22
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 39; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> of 41</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GLUCOTRACK,
    INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">301
    Rte. 17 North, Ste. 800,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rutherford,
    NJ 07070</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Goode</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
    pvgoode@glucotrack.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to (which shall not constitute notice):</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Mannheim, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson Mullins Riley &amp; Scarborough LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">301 Hillsborough Street, Suite 1400</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raleigh, NC 27603</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail: david.mannheim@nelsonmullins.com</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE TO SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">Glucotrack, inc.</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile
Number of Authorized Signatory: __________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser (and delivery of Warrants):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Applicable Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
(if applicable) _________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: (if applicable)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
A Warrants: __________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B Warrants: __________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE TO SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>gctk-20241112.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWHybP9z5Z8GekhvWB/bYnarycs3kKUgid6GPwmoXsF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:GCTK="http://glucotrack.com/20241112" elementFormDefault="qualified" targetNamespace="http://glucotrack.com/20241112">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://glucotrack.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gctk-20241112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gctk-20241112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>gctk-20241112_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>gctk-20241112_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://glucotrack.com/role/Cover" xlink:href="gctk-20241112.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45764183405552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GLUCOTRACK,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0668934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301
    Rte. 17 North<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Ste. 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rutherford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-7715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GCTK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MO#(7FZ'@4._V!#B^5LJ\#^Q[<_FSQ_!?4$L#!!0    ( *.(<EF?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( *.(<ED'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ HXAR64FJ
M)$?O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ HXAR69E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "CB')9WJWV#4\$   "
M$0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ HXAR69^@&_"Q @  X@P   T              ( !DPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "CB')9EXJ[',     3 @  "P
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52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>gctk-20241112.xsd</File>
    <File>gctk-20241112_lab.xml</File>
    <File>gctk-20241112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "GCTK",
   "nsuri": "http://glucotrack.com/20241112",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "gctk-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gctk-20241112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gctk-20241112_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://glucotrack.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001493152-24-046564-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-046564-xbrl.zip
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MQO!28;A)&KNXY8%'H+'&Y?-.);I#'?9>$Y]2OJ+6%I]K)H<6+XU&PE41$R_
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M,[@[6'B1)1[D"W,)T:%)J<J8:!FC_"U1Z6$3A&=$-3ZCP?Z[*-^2/<G$W#!
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MKG3O:;\UH%Z':F A**V/9.<\8@I N+/_)K;7>F3Y3SMDN2TXO"7L>0<(WV!
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MLF "VSW;AQ 9MS'?G AIJ0(3)]_Q7FW&I%P!O6MH[8[?9(,FY0I"U[%Q&?#
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MK5>P3O /7G+GK=1EA+TY_*Y^'#UT"D%,H #QHN#5XRB*#'O5PT@48X3H1_V
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MW<.4'^Y@RCN8\N;K$VY\,QX1_T3C\T_<J'-O]$3"H2"D:]22!1!*3IOA:$D
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M"8/K",V5T$]Y<DHW(7Z'D \$0JS(.89 4L2Q1V^5X*)U-+ET\X9\5GK;FS6
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M41?,W\-=!>O!@-A8P?T3+)(CA#(UQM,UK;0\7*PX<RL6'+'6R2YG<W!_"D-
MJMXMT](W]/ 'YD%@N&OO*BW=-ILH!1*G=._.]K1@E'MQ3+U(50L4O,WF:#4
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ME=A;90PE[,&;H^]6DYWD5"0N%8@*<\L=4S;1%1QF$HAUT<0EN"L29T0X<:>
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MYTN8,5'"1O(-']>:^:F8$DV;MLW,570TRZ?HLLI;MO1R[8 ^@3-I6,8WUP"
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M<5C)-7N1-SRN'I[!OCLXDKAKZ50N][;0]"B.Z+$62= B#B(X32>ER3_J'?,
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MK HQVAU79DX#1UW&=DY1W^F<\B$8BZ%HF$A]H=HE&M4\=+?H'J*)/[U_C^P
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M5HL49(<(5F$L%"GGE'+/^7PJ7CU2Q>%-I3[&Q.6*EAT=H6MZ7Z/44C]94C6
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M(T!.3(\Q)4DQYT:ZR#I'+G@BL&?L)R:)S8_--1PB@')-NY*E?C;8;,]Q3@P
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MW%@N'Z:"T&0^,68@[QI5IIFNRW((T:!)>BJR>5.%\Y'BTJ#H,U*0Z:O+K^)
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MSW%6P-V= 8^]L9D;C*2W/6/'O\YMV32-U\TC-Q3/QLU,Y2*7DK4WGB=1D3*
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M64BMK?W?^N+WK"O&M")AC7-'X@@5"\;:0%4>]+T?14\?I_AC-MS=>2N5/9H
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M]SLT!,88;V6LX2,X:RV92G&GNNR02O84(6<V3)7-^Z+B;%^A_$N+XPJM:*A
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M:JIRW<X$BY6)R& P1'(J(UXKJX.*?<>$<J,@5$<">D&%L1I QO! )H%8DSG
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ME^,TJW?KT0<O,CK\710[E6'+QZU+X"&]Z9.LIQ,6 D:<!@M!3]&-%*$IM*;
M0:! AT_;?D/ ]5'LW<=U#)%<X;MJ_/')AZ7SXGH)_S$[!4'_E&+[( J;H7=3
M>_K%09A?D4=VW\5I++1?D=EN8A>>?&D.7UHM);+FUG(_N19&TSLOBZURA!7!
M*@>&1Z(#(^%83&9T'T&<F!P%\;O9_70,B&7K)R*5)UQT@H/1Y/E'2]T'?<?S
M5+ES-JB$3D7GW=L-=]NNB&UZ=ZW^C]<_'IQ='!^^.]K=^9N9B-<_/L >_')\
M#M;NP<G1Z8?SA]B'1W18O]RC\ID+/F4+T8N\\.-OS%=F#^.)L(_KS&)C(4G=
M2(2N:'=2+11T*"U-(YV3C F]GF5M4^68]&6LF7K(35JE+"Q@;3[DJ.X4'ZJ/
M<F972!QV=Z26%MB " #$#)%4E(U<#4#!CKX>Q=:+J3GU!R_;F5<]%A2^*F#N
M*X!K"*@*!CV%7S"T"G]FK=V2![5U<T01[XS&R0$X)1>.]PP77."4Y)8YDZF7
MA3O>]GZ-AB>/PW![QM^SKKS<(\C&6Z''/&(F5D_=-6M4!N9VYK/L Y?/P?6Q
MU 2.S XJU)S@/C@:6)1,G1AK!?<9D[ZF: ZMRM8Z"5R&;[Y8M[3/..0]457,
M]KD=#M(E<UV/,>QNLU"">BA(P)%BN *_I91H*IX)'0\=>T<?<]':92R-9U%Y
MH,"@:#@.QD#3F\;BZ%BIFRN_F,A3C:W[9)*MR7%N&J&FP1R+=6>-^]M"Q)V;
MW^55%HY)Z\S1R0:$4^H;*G0^3*&,:[%,VNSW7$^+^WFRH@Q.?E60SQBKS[(#
MRHU645M>35NQZ'O;E9=[!,$X*ENS(-W:=[Y9C^*)SQ9"L /,+7(4@"DJN)@"
M<-*<1Z;/TNL\*(6-S@BP*E:B*"!Y<^W";N"B%K[I[;^;%8CUY!,B!*+*?T4)
M"Q_Q7HW9L Q9/-@NX!VL7R]ZI"T>;:YF0YJK<MR4\$$K :E*)E3M0KA\-X;Q
M$=OND7O6E9=[^RRHCEIZ3",I1RX%+*CR1&)U@,I9E0SX:Y@9' [)0A_^8&&!
M$=<Z"@E/3(2,8D57;-8DB]&XX(3#HE^:%Q +-J?UKZSZL:5EJ:8_")D_1=>J
M*27>62L'KV(M[EL%G4%Y$W>C "_B-!MC08CEBG&_$%)&T/O*BCGP>QMS@E+X
M3!A#OY],,%F<Z3 ?M[TQ4YUA902D4!I^!@1SV:3-6H(V,+W'RQ]>/$V6>XN]
M9 !3_/>J_I@F)W_'[@Y]]BYCD"L-@M(L(L]6#Y *?4.%%2$]8Y7\D4.UN],W
M5K;<&GH_R=8V:XZA-J_3(/_B*# V#R8A?+WAA/)YQCI4 *1X7DXV.D%F<*%[
ME.V?8F@=S)4/>^=["3DY3(0XKBY+E)6 A'")?@X0KQ<Y$F!=\3R PB34)"&J
M;X4,;..\6%J%'1M[NYY5"V_!%VJ#TI[$?45WH0R^Y;R7G4^LA]ZF=VCX!I76
M;K>J>::^G'0XUME9[?"-0NA?5#I<<4."=+C7EPT:XB.JHJ+2S'].0OQ1W%&/
MZKJEA,&!L%DTKY)?$>WOJA "?'\L.(4I TDA%/ OQXC!(@H+PKQSA0O*X4E8
MB#PO4F: O0K?#U%(I2/<Z,B>P8&@LHQD+3K*(TM6]?+IWK-_2[ "S*Q2NJ)I
M0U#"C*I?*Q8JAOTVK@M2[CU@E1!G*@R@EM?CN8I2KJ*)X"%KH88S@K*B&HO4
M.S1!UY,JT_#H](0^IJXJC49?S1-4$J+(4^H.+ZU6H8;2+^BHI=0#\/[ IX+
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MO>*8(+J+LVI-D$@*?09*@/.'\URJR91:-QF_(^,A3=)X(;%\'0(]^DWB['A
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M;7( B2_.M76KZ_5.8P$28'L2##[_L[&@=FLJWZ8$'Z]D79;*\<-&Z?&"L>$
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M,@E]N7>KC=SNBQ^1> B1P)>]V%'>RQG<P0O4!O<E#:-J2 @>!?@#2:-;^)R
M795M@.<3XL2ZA,B;V["AIS>@_:K:0^SY^JKR?=M%_CU!/4(&5G<O"?E/32<'
M<+%%4(4*R!C:H:A9+[#I6;%$S6OQA^BDY(D"U(5P"MAQ^8AAQBG9K6L4'K)
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M55UPK+XHG!GCU&%(_A=A=R4&$FYHI2OHX&8R! UM$OQR&5//S<8J<J12$N@
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M%+%F$C;$&&"L1N*N@-#![C'TK37<(1ZP+HBR4BHH$C:\;?C*X7]'!Q /[S-
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M^K+RIC6'B\"M5BJ>^WK7ZR<X*P4V9I2P\2:X5Z_7W<2;0TO(V4#07+KF&O<
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M:RYH=&U02P$"% ,4    " "CB')9'(YJ&2H#  #I"P  $0
M@ %Z\   9V-T:RTR,#(T,3$Q,BYX<V102P$"% ,4    " "CB')9%0.^.OX*
M  " A@  %0              @ '3\P  9V-T:RTR,#(T,3$Q,E]L86(N>&UL
M4$L! A0#%     @ HXAR69.U98'<!P  ]%X  !4              ( !!/\
L &=C=&LM,C R-#$Q,3)?<')E+GAM;%!+!08     !0 % #8!   3!P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gctk-20241112.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-12" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-12" id="Fact000004">0001506983</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-12" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-12" id="Fact000010">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-12" id="Fact000011">GLUCOTRACK, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-12" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-12" id="Fact000013">001-41141</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-12" id="Fact000014">98-0668934</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-12" id="Fact000015">301     Rte. 17 North</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-12" id="Fact000016">Ste. 800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-12" id="Fact000017">Rutherford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-12" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-12" id="Fact000019">07070</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-12" id="Fact000020">(201)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-12" id="Fact000021">842-7715</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-12" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-12" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-12" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-12" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-12" id="Fact000026">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-12" id="Fact000027">GCTK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-12" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-12" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
